ArticleInternational journal of clinical and experimental pathology2017
CCL4 promotes the cell proliferation, invasion and migration of endometrial carcinoma by targeting the VEGF-A signal pathway.
Article in International journal of clinical and experimental pathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 21 citations in OpenAlex.
- Genetically Predicted Circulating Levels of Cytokines and the Risk of Cancer.Frontiers in immunology · 2022Pooled it
- Efficacy and Safety of Bevacizumab-Combined Chemotherapy for Advanced and Recurrent Endometrial Cancer: A Systematic Review and Meta-analysis.Balkan medical journal · 2021Pooled it
- Integrative Analysis of Multiomic Pathways Predicts Cancer-Affected Lobes in Lung Cancer.Cancer prevention research (Philadelphia, Pa.) · 2026Article
- HPV-driven inflammatory pathways in ovarian carcinogenesis: molecular mechanisms and emerging therapeutic interventions.Journal of ovarian research · 2025Review
- Chemokines and Cytokines in Immunotherapy of Melanoma and Other Tumors: From Biomarkers to Therapeutic Targets.International journal of molecular sciences · 2024Review
- Cyclin Dependent Kinase Inhibitor 2A Genetic and Epigenetic Alterations Interfere with Several Immune Components and Predict Poor Clinical Outcome.Biomedicines · 2023Article
- The Chemokine CCL4 Stimulates Angiopoietin-2 Expression and Angiogenesis via the MEK/ERK/STAT3 Pathway in Oral Squamous Cell Carcinoma.Biomedicines · 2022Article
- Mapping the developing human immune system across organs.Science (New York, N.Y.) · 2022Article
- Review
- The Exploration of Chemokines Importance in the Pathogenesis and Development of Endometrial Cancer.Molecules (Basel, Switzerland) · 2022Review
- The Association of CCL4 rs1634507 and rs10491121 Polymorphisms with Susceptibility of Oral Squamous Cell Carcinoma in an Iranian Population: A Case-Control Study.Iranian journal of pathology · 2022Article
- Adaptive transcriptomic and immune infiltrate responses in the tumor immune microenvironment following neoadjuvant chemotherapy in high grade serous ovarian cancer reveal novel prognostic associations and activation of pro-tumorigenic pathways.Frontiers in immunology · 2022Article
- Review
- miR-29a-3p inhibits endometrial cancer cell proliferation, migration and invasion by targeting VEGFA/CD C42/PAK1.BMC cancer · 2021Article
- CC Chemokines in a Tumor: A Review of Pro-Cancer and Anti-Cancer Properties of Receptors CCR5, CCR6, CCR7, CCR8, CCR9, and CCR10 Ligands.International journal of molecular sciences · 2020Review
- Hypoxia Alters the Expression of CC Chemokines and CC Chemokine Receptors in a Tumor-A Literature Review.International journal of molecular sciences · 2020Review
- Bioinformatics prediction and analysis of hub genes and pathways of three types of gynecological cancer.Oncology letters · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chemokine (C-C motif) ligand 4 (CCL4) and vascular endothelial growth factor-A (VEGF-A) are involved in the progression and metastasis of some tumors, including ovarian cancer, colon cancer and prostate cancer. However, the roles of CCL4 and VEGF-A in human endometrial cancer (EC) are still unclear. Here, we demonstrated that the production of CCL4 and VEGF-A was significantly higher in EC tissues than in normal tissues, and their expression profiles were associated with the clinical stage of EC. In addition, we found that CCL4 promoted the angiogenesis and invasive ability of EC tumors by increasing the production of VEGF-A. We further confirmed the effect of CCL4 in the growth of EC tumors by silencing the expression of CCL4 in EC cell lines. Finally, we found that CCL4 upregulated VEGF-A expression by activating STAT3, and it enhanced the progression and metastasis of EC. Our study showed that CCL4 promoted tumor growth by upregulating VEGF-A expression, which affected the STAT3 signal pathway in the EC cells.
Indexed as
Identifiers
31966483PMC6965868W3007380027What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.